US 12,351,618 B2
Engineered trimeric CD70 proteins and uses thereof
Carla A. Jaeger, Seattle, WA (US); Colin E. Correnti, Seattle, WA (US); and Stanley R. Riddell, Sammamish, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Appl. No. 17/767,843
Filed by Fred Hutchinson Cancer Center, Seattle, WA (US)
PCT Filed Oct. 8, 2020, PCT No. PCT/US2020/054855
§ 371(c)(1), (2) Date Apr. 8, 2022,
PCT Pub. No. WO2021/072127, PCT Pub. Date Apr. 15, 2021.
Claims priority of provisional application 62/984,695, filed on Mar. 3, 2020.
Claims priority of provisional application 62/971,712, filed on Feb. 7, 2020.
Claims priority of provisional application 62/912,510, filed on Oct. 8, 2019.
Prior Publication US 2023/0174618 A1, Jun. 8, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/21 (2006.01); C07K 14/435 (2006.01); C07K 14/725 (2006.01); C07K 14/78 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/70575 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4204 (2025.01); A61K 40/4211 (2025.01); A61K 40/4252 (2025.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/21 (2013.01); C07K 14/43504 (2013.01); C07K 14/43563 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 14/78 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2239/22 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/20 (2013.01); C07K 2319/21 (2013.01); C07K 2319/22 (2013.01); C07K 2319/30 (2013.01); C07K 2319/41 (2013.01); C07K 2319/42 (2013.01); C07K 2319/43 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01)] 18 Claims
 
1. An ex vivo method of manufacturing a T cell population for administration to a subject, the method comprising:
obtaining a population of T cells;
culturing the population of T cells within a culture media comprising:
a CD3 stimulating molecule and an Fc-dimerized protein at a concentration sufficient to increase T cell activation, wherein the Fc-dimerized protein has two copies of the single chain protein sequence as set forth in SEQ ID NO: 5 or a sequence having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 5 to create an activated T cell population;
culturing the activated T cell population within a culture media lacking the CD3 stimulating molecule; and
formulating the expanded T cell population into a pharmaceutically acceptable carrier in a therapeutically effective amount,
thereby ex vivo manufacturing the T cell population for administration to the subject.